Key result
ACEI or ARB therapy linked to lower severe disease rates in COVID-19 with hypertension.
Observational
The dysfunction of the renin-angiotensin system (RAS) has been observed in coronavirus infection disease (COVID-19) patients, but whether RAS inhibitors, such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II type 1 receptor blockers (ARBs), are associated with clinical outcomes remains unknown. COVID-19 patients with hypertension were enrolled to evaluate the effect of RAS inhibitors. We observed that patients receiving ACEI or ARB therapy had a lower rate of severe diseases and a trend toward a lower level of IL-6 in peripheral blood. In addition, ACEI or ARB therapy increased CD3 and CD8 T cell counts in peripheral blood and decreased the peak viral load compared to other antihypertensive drugs. This evidence supports the benefit of using ACEIs or ARBs to potentially contribute to the improvement of clinical outcomes of COVID-19 patients with hypertension.
No takes yet. Share an insight, caveat, or question.
Meng et al. (2020) conducted an observational in COVID-19 with hypertension. ACEI or ARB therapy (RAS inhibitors) vs. Other antihypertensive drugs was evaluated on Rate of severe diseases. ACEI or ARB therapy in COVID-19 patients with hypertension was associated with a lower rate of severe diseases and decreased peak viral load compared to other antihypertensive drugs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: